Four Fab 5% Yielders! AstraZeneca plc, Standard Life Plc, eSure Group PLC & Vodafone Group plc

Royston Wild discusses the dividend prospects of AstraZeneca plc (LON: AZN), Standard Life Plc (LON: SL), eSure Group PLC (LON: ESUR) and Vodafone Group plc (LON: VOD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m running the rule over four FTSE-quoted dividend giants.

Global greatness

With earnings expected to explode this year and beyond, I reckon dividend hunters should give insurance star Standard Life (LSE: SL) more than a passing glance.

The business is rapidly expanding overseas to underpin future profits growth, a strategy that helped net inflows to more than double in 2015 to £12.6bn. Indeed, more than two-thirds of these inflows came from outside the UK.

With Standard Life’s leading position in the fast-growing savings and pensions markets paying off handsomely, a dividend of 18.36p per share in 2015 is expected to rise to 19.7p this year, and again to 21.2p in 2017. Consequently the insurer carries market-smashing yields of 5.4% and 5.8% for these years.

Motoring higher

Diversified insurer Esure (LSE: ESUR) is well placed to enjoy the end of the low-premium era, in my opinion. A backdrop of rising policy costs underpinned a 30% uptick in pre-tax profits last year, to £134m, and further hefty gains would appear to be on the cards.

Gross written premiums advanced 6.3% in 2015, and Esure expects premiums to advance between 10% and 15% in the current period. As well as benefitting from rising prices, Esure is also growing its customer base in the critical Motor segment.

The business was forced to cut the dividend in 2015 to build its capital pile, reducing the payment to 11.5p per share from 16.8p the previous year.

But with market conditions steadily improving, the City has chalked-in dividends of 13.2p for 2016 and 15.5p for next year. These figures create gigantic yields of 4.9% and 5.8%, respectively.

A mobile master

Telecoms titan Vodafone’s (LSE: VOD) heavy spending of recent years continues to deliver stonking returns. The company has thrown vast amounts into improving its data and voice capabilities, moves that have steadily improved its performance in its critical European marketplaces.

Vodafone’s Project Spring organic investment scheme has also enabled it to take advantage of surging demand across Asia, the Middle East and Africa. And sales from these regions should keep galloping amid exploding population growth and rising income levels.

With earnings expected to start moving higher again from next year, Vodafone is expected to fork out dividends of 11.5p per share for the periods concluding March 2016 and 2017, respectively, yielding a handsome 5.3%.

In good health

I believe the dependable nature of medicines demand should power earnings — and consequently dividends — at pharma giant AstraZeneca (LSE: AZN) through the roof in the coming years.

Sure, the issue of patent losses on key labels is set to remain an anchor around the bottom line for some time yet — the City expects AstraZeneca to rack up further bottom-line slides in 2016 and 2017.

But AstraZeneca is pulling out all the stops to offset these losses, culminating in a 21% hike in R&D spend in 2015 alone. A subsequent improvement in the firm’s product pipeline should provide ample rewards as healthcare spend explodes across the globe, in my opinion.

The dividend is expected to remain locked at 280 US cents through to the close of next year. But this still yields a handsome 4.8%, and I expect this figure to march higher again in the years ahead as profits advance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should I buy National Grid shares for the big dividend before it’s too late?

This year's price weakness has left National Grid shares on what looks like a tempting valuation. I hope it doesn't…

Read more »